| Literature DB >> 28424369 |
Jia Zheng1, Sheng Zheng2, Qianyun Feng2, Qian Zhang1, Xinhua Xiao3.
Abstract
Obesity is a growing public health problem, which has now been considered as a pandemic non-communicable disease. However, the efficacy of several approaches for weight loss is limited and variable. Thus, alternative anti-obesity treatments are urgently warranted, which should be effective, safe, and widely available. Active compounds isolated from herbs are similar with the practice of Traditional Chinese Medicine, which has a holistic approach that can target to several organs and tissues in the whole body. Capsaicin, a major active compound from chili peppers, has been clearly demonstrated for its numerous beneficial roles in health. In this review, we will focus on the less highlighted aspect, in particular how dietary chili peppers and capsaicin consumption reduce body weight and its potential mechanisms of its anti-obesity effects. With the widespread pandemic of overweight and obesity, the development of more strategies for the treatment of obesity is urgent. Therefore, a better understanding of the role and mechanism of dietary capsaicin consumption and metabolic health can provide critical implications for the early prevention and treatment of obesity.Entities:
Keywords: Capsaicin; TRPV1; adipogenesis; appetite; brown adipose tissue; obesity
Mesh:
Substances:
Year: 2017 PMID: 28424369 PMCID: PMC5426284 DOI: 10.1042/BSR20170286
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1The molecular structure of capsaicin isolated from chili peppers
Clinical studies of the weight-loss effects of capsaicin
| Treatments | Year | Country | Study design | Subjects included | Baseline BMI | Sample size | Age (years) | Outcomes | Adverse events | Potential mechanism | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capsinoids (6 mg per day for 12 weeks) | 2009 | U.S.A. | Double-blind, randomized, placebo-controlled trial | Overweight individuals | 30.6 ± 2.4 | 42 ± 8 | Body weight decreased 0.92 kg; abdominal fat decreased 1.11% | None | Increase in fat oxidation and genetic polymorphisms | Snitker et al. [ | |
| Red pepper (capsaicin 10 g single meal) | 1999 | Canada | Prospective study | Healthy individuals | 25.3 ± 4.7 | 25.8 ± 2.8 | Decreased appetite | None | Increase in sympathetic nervous system activity | Yoshioka et al. [ | |
| Capsinoids (10 mg/kg per day for 4 weeks) | 2007 | Japan | Double-blind, randomized, placebo-controlled trial | Men and postmenopausal women | >23 | 30–65 | Body weight tended to decrease during the 2- to 4-week period | None | Increased VO2, energy expenditure, and fat oxidation | Inoue et al. [ | |
| Capsaicin (135 mg per day for 3 months) | 2003 | Netherlands | Randomized double-blind placebo-controlled study | Moderately overweight subjects | 29.3 ± 2.5 | 18–60 | Significant increase in resting energy expenditure | None | More sustained fat oxidation | Lejeune et al. [ | |
| Capsinoids (9 mg per day for 8 weeks) | 2016 | Japan | Randomized double-blind placebo-controlled study | College students | 21.4 ± 1.8 | 20.7 ± 1.2 | Increased brown adipose tissue (BAT) density | None | Increased BAT activity | Nirengi et al. [ |
Preclinical studies about anti-obesity effects of capsaicin
| Treatments | Species | Duration | Metabolic disorders | Potential mechanism | Reference |
|---|---|---|---|---|---|
| 0–250 μmol/l capsaicin | 3T3-L1 preadipocytes and adipocytes | 24–72 h | Decreased the amount of intracellular triglycerides, GPDH activity | Inhibited the expression of PPARγ, C/EBP-α, and leptin | Hsu et al. [ |
| Induced apoptosis | Induced up-regulation of adiponectin at the protein level | ||||
| Inhibited adipogenesis | |||||
| 1 μmol/l capsaicin | 3T3-L1 preadipocytes | 3–8 days | Prevented the adipogenesis | Increased intracellular calcium | Zhang et al. [ |
| 0.015% capsaicin | Male C57BL/6 mice | 10 weeks | Decreased triglyceride levels | Decreased TRPV-1 expression in adipose tissue | Kang et al. [ |
| Lowered fasting glucose, insulin, and leptin levels | Increased mRNA/protein of adiponectin in the adipose tissue | ||||
| Increased PPARα/PGC-1α mRNA in the liver | |||||
| 10 mg/kg body weight capsaicin | Std ddY mice | 2 weeks | Lower body weight | Increased oxygen consumption | Ohnuki et al. [ |
| Markedly suppressed body fat accumulation | Stimulated the secretion of adrenalin | ||||
| Decreased triglyceride levels | |||||
| 0.3% capsinoids | C57BL/6J mice | 8 weeks | Suppressed body weight gain under the HFD | Increased energy expenditure | Saito et al. [ |
| Decreased plasma cholesterol level | Activation of fat oxidation in skeletal muscle | ||||
| Prevented diet-induced liver steatosis | Activation lipolysis in BAT | ||||
| Increased cAMP levels and PKA activity in BAT | |||||
| 0.003%, 0.01%, and 0.03% capsaicin | wild-type and TRPV1−/− mice | 16 weeks | Promoted weight loss | Increased the expression of UCP-1, BMP8b, SIRT-1, PGC-1α, and PRDM-16 in BAT | Baskaran et al. [ |
| Enhanced the respiratory exchange ratio | Increased the phosphorylation of SIRT-1 | ||||
| Countered hypercholesterolemia | |||||
| 0.01% capsaicin | wild-type and TRPV1−/− mice | 26 weeks | Countered obesity | Promoted SIRT-1 expression | Baskaran et al. [ |
| Browning of WAT | Increased the expression of PGC-1α | ||||
| Facilitated PPARγ–PRDM-16 interaction | |||||
| 0.01% capsaicin | wild-type and TRPV1−/− mice | 24 weeks | Ameliorated abnormal glucose homeostasis | Activation of TRPV1-mediated GLP-1 secretion in the intestinal cells | Wang et al. [ |
| Increased GLP-1 levels in the plasma and ileum | |||||
| 640 μmol/L, 2 ml/kg capsaicin | Sprague-Dawley rats | 15 min | Increased superior mesenteric artery blood flow | Induced a dichotomous pattern of blood flow changes | Leung et al. [ |
| Reduction in hydrogen gas clearance | |||||
| 0.01% capsaicin | C57BL/6J male mice | 9 weeks | Reduced weight gain | Modest modulation of the gut microbiota | Shen et al. [ |
| Improved glucose tolerance | Up-regulated the expression of |
BMP8b, bone morphogenetic protein-8b; cAMP, cyclic adenosine monophosphate; C/EBP-α, CCAAT-enhancer-binding protein-α; GPDH, glycerol-3-phosphate dehydrogenase; Muc2, mucin 2 gene; PGC1-α, PPARγ co-activator 1-α; PKA, protein kinase A; PRDM-16, positive regulatory domain containing 16; Reg3g, regenerating islet-derived protein 3γ; SIRT-1, sirtuin-1; UCP-1, uncoupling protein 1; WAT, white adipose tissue.
Figure 2Molecular mechanisms of the anti-obesity effects of capsaicin
(A) Capsaicin can inhibit adipogenesis in preadipocyte and adipocyte by up-regulating the expression of PPARγ and UCP-1. Thus, it will stimulate adiponectin secretion and increase body fat accumulation. (B) Capsaicin can activate BAT activity, accompanied by increased expression of UCP-1 and PGC-1α. (C) Capsaicin can suppress appetite, increase satiety, and ameliorate insulin resistance. (D) Capsaicin can modulate its function in gastrointestinal tract and gut microbiome, including stimulation of GLP-1 secretion and increase in population of the gut bacterium Akkermansia muciniphila. STAT-3, signal transducer and activator of transcription-3.